People · Operator
Named in public records as an officer, director or promoter · active 2015–2026 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Iliad Biotechnologies, Inc. | — | Biotechnology | Series D+ | $115.5M | $747.3M | 2026 |
| Iliad Biotechnologies, Llc | — | Biotechnology | Series C | $98.3M | $52.0M | 2015 |
KEITH RUBIN at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside KEITH RUBIN on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Avi Naider | 2 | 6 |
| Eric Edidin | 2 | 3 |
| David Johnston | 1 | 8 |
| Cuong Do | 1 | 4 |
| Mario Barro | 1 | 3 |
| William Steinkrauss | 1 | 1 |
| KEN SOLOVAY | 1 | 1 |
| Corey Horowitz | 1 | 1 |
| Bin Yan | 1 | 1 |
| Ariel Pablos-Mendez | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.